Summary
The Trump administration is a considering issuing an executive order to address to rising costs of prescription drugs which is likely to be “industry-friendly,” as reported by Kaiser Health News (KHN) and Politico. Notably, the order will not allow the government to negotiate drug prices or allow importing of drugs from other countries, both solutions Trump proposed during his campaign. Instead, the executive order will likely include more targeted approaches that would likely be favored by industry, according to KNH and Politico.